Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

About this update from Pyxis Oncology, Inc.

Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC maMICVO monotherapy modulated the tumor-immune environment in a syngeneic preclinical model of HNSCC toward a more favorable immune-permissive environment for immunotherapy maMICVO in combination with anti-mouse PD-1 worked synergistically to produce greater anti-tumor activity compared with either treatment alone in an immune-refractory syngeneic preclinical model of HNSCC Preclinical findings support the ongoing clinical development of MICVO as both monotherapy and in combination with pembrolizumab for R/M HNSCC BOSTON, April 17, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will present new preclinical data highlighting that a mouse analogue of MICVO (maMICVO) demonstrates anti-tumor activity in a preclinical head and neck squamous cell carcinoma (HNSCC) model as monotherapy, and synergistic anti-tumor activity in combination with anti-mouse PD-1. These data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, held April 17 – April 22, 2026. “These new preclinical data are particularly compelling as they further reinforce MICVO’s clinical development in HNSCC, both as a novel monotherapy treatment and in combination with anti-PD-1,” said Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology. “An important finding from the data is that combination treatment with maMICVO and anti-mouse PD-1 demonstrated synergistic anti-tumor activity and greater tumor control than either treatment alone in an immunotherapy-refractory preclinical HNSCC model, highlighting MICVO’s novel three-pronged mechanism of action and its potential to meaningfully enhance response to immunotherapy. Following our mid-year 2026 MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC, we look forward to sharing updated data from the ongoing Phase 1/2 combination dose escalation study of MICVO in combination with pembrolizumab for 1L/2L+ R/M HNSCC patients in the second half of 2026.” Micvotabart pelidotin (MICVO), is a first-in-concept antibody drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a ...

View stock analysis, news, and events for Pyxis Oncology, Inc.